Logos Global Management’s Structure Therapeutics GPCR Stock Holding History

Logos Global Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.1M	Sell	500,000 -100,000	-17%	-$6.84M	1.2%	29
2025 Q4	$41.7M	Sell	600,000 -250,000	-29%	-$10.2M	2.52%	10
2025 Q3	$23.8M	Hold	850,000	–	–	2.13%	19
2025 Q2	$17.6M	Buy	850,000 +425,000	+100%	+$9.34M	1.95%	19
2025 Q1	$7.36M	Sell	425,000 -275,000	-39%	-$6.74M	1.31%	23
2024 Q4	$19M	Sell	700,000 -550,000	-44%	-$19.5M	2.22%	16
2024 Q3	$54.9M	Buy	1,250,000 +150,000	+14%	+$5.8M	5.92%	2
2024 Q2	$43.2M	Buy	1,100,000 +379,942	+53%	+$15.6M	3.47%	8
2024 Q1	$30.9M	Sell	720,058 -350,000	-33%	-$14.8M	2.5%	13
2023 Q4	$43.6M	Buy	1,070,058 +570,058	+114%	+$32.7M	4.07%	9
2023 Q3	$25.2M	Buy	500,000 +100,000	+25%	+$3.22M	3.36%	8
2023 Q2	$16.6M	Buy	400,000 +50,000	+14%	+$1.4M	2.26%	16
2023 Q1	$8.33M	Buy	+350,000	New	+$8.22M	1.19%	31

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Logos Global Management's GPCR Position: Q1 2026 in Review

Logos Global Management reduced its Structure Therapeutics (GPCR) stake by 17% in Q1 2026, selling an estimated $6.84M and leaving 500,000 shares worth $24.1M. The position accounts for 1.2% of the portfolio, ranked #29.

Logos Global Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $54.9M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Logos Global Management held 500,000 shares of Structure Therapeutics worth $24.1M as of Q1 2026.
Logos Global Management sold 100,000 Structure Therapeutics shares in Q1 2026, an estimated $6.84M.
Structure Therapeutics made up 1.2% of Logos Global Management's portfolio in Q1 2026, its #29 holding.
Logos Global Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
Logos Global Management's Structure Therapeutics position peaked at $54.9M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.